One on one with Claudia Martinez on her take on recent study done by Access to Medicine Foundation on Generics and Biosimilars

Providing context for the report, Martínez discusses the difference between generic medicines and their brand-name counterparts, focusing in particular on efficacy, pricing and safety. She shares an insight into why generic medicines remain out of reach for people living in low- and middle-income countries and why they are critical to expanding access.

Martínez provides an overview of the key findings of the report, which are focused on areas where generic and biosimilar medicine manufacturers can make progress. She sheds light on how these findings can be used to address access barriers and promote public health in Kenya and how Kenyan stakeholders, such as policymakers, healthcare providers and pharmaceutical companies can use the recommendations from the report to improve healthcare access.

She also elaborates on prescription practices where generic medicines are less favoured, and discusses the practice of prescribing the international proprietary name (INN) instead of the brand name.

In concluding the interview, Martínez reflects on the added value of the report: "This report, alongside The Analytical Framework, will both serve as a roadmap for other manufacturers of generic and biosimilar medicines who seek to step up their approach to access to medicine, and as a tool for investors, policymakers, practitioners and patients to engage the generics industry on how to move forward."